丙型肝炎相关肝硬化到2025年将成为住院的 Marginal 原因
该研究在巴塞罗那医院肝脏科登记了2011-2014年(直接抗病毒药物前时代)和2015-2019年(直接抗病毒药物后时代)因肝硬化住院的患者。结果显示,丙型肝炎相关肝硬化住院人数和比例在2011-2014年保持稳定(每年525例,占总数的48.8%),2015年后逐渐下降(P<0.001),到2019年降至不到300例(27.1%)。通过斜率分析预测,到2025年丙型肝炎相关肝硬化住院将仅占2.3%(95%CI 0-10.9%)。
要点
- 丙型肝炎相关肝硬化住院比例从2011-2014年的48.8%降至2019年的27.1%。
- 预测到2025年丙型肝炎相关肝硬化住院将仅占2.3%(95%CI 0-10.9%)。
- 同期代谢相关脂肪性肝病住院增加5倍,自身免疫性肝炎住院增加4倍。
核心结论
- 自2015年以来,丙型肝炎相关肝硬化住院负担大幅下降,与西班牙广泛使用直接抗病毒药物(DAA)时间吻合。
- 预测到2025年,丙型肝炎相关肝硬化将成为肝病患者住院的 marginal 原因。
研究设计与样本
- 登记2011-2014年(DAA前)和2015-2019年(DAA后)期间在巴塞罗那医院肝脏科因肝硬化住院的病例。
- 共登记14865例住院,其中10053例因肝硬化住院(对应6272例患者)。
主要发现
- 丙型肝炎相关肝硬化住院人数和比例在2011-2014年保持稳定(每年525例,占总数的48.8%),2015年后逐渐下降(P<0.001),2019年降至不到300例(27.1%)。
- DAA前时期丙型肝炎相关肝硬化住院日每年为3885天(44.9%),2015年后持续下降(P>0.001),2019年仅为1909天(22%)。
- 重症监护室入院人数呈现类似趋势。
- 通过斜率分析(二项回归模型)预测,到2025年丙型肝炎相关肝硬化住院将仅占2.3%(95%CI 0-10.9%)。
- 研究期间代谢相关脂肪性肝病住院增加5倍,自身免疫性肝炎住院增加4倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Complications of cirrhosis are the main cause of hospital admissions in liver units. In areas where HCV is prevalent, most of these admissions are attributable to HCV-related cirrhosis (HCV-cirrhosis). This study assessed the impact of direct-acting antivirals (DAA) in the profile of patients with liver disease admitted to a referral liver unit from a university hospital. METHODS: We registered hospital admissions resulting from cirrhosis to the Liver Unit of the Hospital Clinic of Barcelona, from 2011 to 2014 (pre-DAA period) and from 2015 to 2019 (post-DAA period). RESULTS: From a total of 14,865 hospital admissions, 10,053 resulted from cirrhosis (corresponding to 6,272 patients). The number and proportion of hospital admissions because of HCV-cirrhosis remained stable during the period 2011-2014 (525 per year, 48.8% of the total), but decreased progressively after 2015 (p <0.001), reaching <300 (27.1%) admissions in 2019. Similarly, HCV-cirrhosis accounted for 3,885 inpatient days per year (44.9%) during the pre-DAA period and decreased steadily after 2015 (p >0.001), reaching only 1,909 inpatient days (22%) in 2019. The figures for intensive care unit admissions followed a similar pattern. By means of a slope analysis (binomial regression model), we predicted that HCV-cirrhosis hospital admissions will be residual by 2025 (2.3%, 95% CI 0-10.9%). By contrast, we observed a significant increase in hospital admissions because of metabolic-associated fatty liver disease (5-fold) and autoimmune hepatitis (4-fold) during the study period. CONCLUSIONS: In summary, our data showed a profound reduction in HCV-cirrhosis hospitalisation burden since 2015, coincident with the wide use of DAAs in Spain. Our predictions suggest that, by 2025, HCV-cirrhosis will be a marginal cause of hospital admissions for patients with liver disease. LAY SUMMARY: Over the past few years, the wide use of antiviral drugs that cure HCV has had a significant effect on patients being admitted to hospital. Most patients with HCV and cirrhosis are treated (and often cured) in the community and, thus, the number of hospital admissions because of severe forms of HCV has decreased drastically. HCV is no longer the first cause of admission into liver units and, in only a few years from now, it is likely to be only a residual cause of hospitalisation.
引用
- Rodríguez-Tajes S, Pocurull A, Castillo J, et al. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol. 2020. PMID: 32697948. doi:10.1016/j.jhep.2020.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。